Serine protease PRSS23 is a newly discovered protein that has been associated with tumor progression in various types of cancers. Interestingly, PRSS23 is coexpressed with estrogen receptor α (ERα), which is a prominent biomarker and therapeutic target for human breast cancer. Estrogen signaling through ERα is also known to affect cell proliferation, apoptosis, and survival, which promotes tumorigenesis by regulating the production of numerous downstream effector proteins. In the present study, we aimed to clarify the correlation between and functional implication of ERα and PRSS23 in breast cancer. Analysis of published breast cancer microarray datasets revealed that the gene expression correlation between ERα and PRSS23 is highly significant among all ERα-associated proteases in breast cancer. We then assessed PRSS23 expression in 56 primary breast cancer biopsies and 8 cancer cell lines. The results further confirmed the coexpression of PRSS23 and ERα and provided clinicopathological significance. In vitro assays in MCF-7 breast cancer cells demonstrated that PRSS23 expression is induced by 17β-estradiol-activated ERα through an interaction with an upstream promoter region of PRSS23 gene. In addition, PRSS23 knockdown may suppress estrogen-driven cell proliferation of MCF-7 cells. Our findings imply that PRSS23 might be a critical component of estrogen-mediated cell proliferation of ERα-positive breast cancer cells. In conclusion, the present study highlights the potential for PRSS23 to be a novel therapeutic target in breast cancer research.
References
[1]
Miyakoshi K, Murphy MJ, Yeoman RR, Mitra S, Dubay CJ, et al. (2006) The identification of novel ovarian proteases through the use of genomic and bioinformatic methodologies. Biol Reprod 75: 823–835.
[2]
Wahlberg P, Nylander A, Ahlskog N, Liu K, Ny T (2008) Expression and localization of the serine proteases high-temperature requirement factor A1, serine protease 23, and serine protease 35 in the mouse ovary. Endocrinology 149: 5070–5077.
[3]
Simpson JC, Wellenreuther R, Poustka A, Pepperkok R, Wiemann S (2000) Systematic subcellular localization of novel proteins identified by large-scale cDNA sequencing. EMBO Rep 1: 287–292.
[4]
Pentecost BT, Bradley LM, Gierthy JF, Ding Y, Fasco MJ (2005) Gene regulation in an MCF-7 cell line that naturally expresses an estrogen receptor unable to directly bind DNA. Mol Cell Endocrinol 238: 9–25.
[5]
Coser KR, Chesnes J, Hur J, Ray S, Isselbacher KJ, et al. (2003) Global analysis of ligand sensitivity of estrogen inducible and suppressible genes in MCF7/BUS breast cancer cells by DNA microarray. Proc Natl Acad Sci U S A 100: 13994–13999.
[6]
Toillon RA, Magne N, Laios I, Castadot P, Kinnaert E, et al. (2007) Estrogens decrease gamma-ray-induced senescence and maintain cell cycle progression in breast cancer cells independently of p53. Int J Radiat Oncol Biol Phys 67: 1187–1200.
[7]
Ifon ET, Pang AL, Johnson W, Cashman K, Zimmerman S, et al. (2005) U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3. Cancer Cell Int 5: 19.
[8]
Jarzab B, Wiench M, Fujarewicz K, Simek K, Jarzab M, et al. (2005) Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res 65: 1587–1597.
[9]
Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801–1806.
[10]
Lippman ME, Rae JM, Chinnaiyan AM (2008) An expression signature of estrogen-regulated genes predicts disease-free survival in tamoxifen-treated patients better than progesterone receptor status. Trans Am Clin Climatol Assoc 119: 77–90.
[11]
Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, et al. (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138: 863–870.
[12]
Tsai MJ, O'Malley BW (1994) Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63: 451–486.
[13]
Rich RL, Hoth LR, Geoghegan KF, Brown TA, LeMotte PK, et al. (2002) Kinetic analysis of estrogen receptor/ligand interactions. Proc Natl Acad Sci U S A 99: 8562–8567.
[14]
Eng FC, Lee HS, Ferrara J, Willson TM, White JH (1997) Probing the structure and function of the estrogen receptor ligand binding domain by analysis of mutants with altered transactivation characteristics. Mol Cell Biol 17: 4644–4653.
[15]
Katzenellenbogen BS (1996) Estrogen receptors: bioactivities and interactions with cell signaling pathways. Biol Reprod 54: 287–293.
[16]
King WJ, Greene GL (1984) Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature 307: 745–747.
[17]
Sommer S, Fuqua SA (2001) Estrogen receptor and breast cancer. Semin Cancer Biol 11: 339–352.
[18]
Hall JM, Couse JF, Korach KS (2001) The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 276: 36869–36872.
[19]
Heldring N, Pike A, Andersson S, Matthews J, Cheng G, et al. (2007) Estrogen receptors: how do they signal and what are their targets. Physiol Rev 87: 905–931.
[20]
Schultz-Norton JR, Ziegler YS, Nardulli AM (2011) ERalpha-associated protein networks. Trends Endocrinol Metab 22: 124–129.
[21]
van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530–536.
[22]
Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155–168.
[23]
Moggs JG, Murphy TC, Lim FL, Moore DJ, Stuckey R, et al. (2005) Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes. J Mol Endocrinol 34: 535–551.
[24]
Lecomte J, Flament S, Salamone S, Boisbrun M, Mazerbourg S, et al. (2008) Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines. Breast Cancer Res Treat 112: 437–451.
[25]
Grisouard J, Medunjanin S, Hermani A, Shukla A, Mayer D (2007) Glycogen synthase kinase-3 protects estrogen receptor alpha from proteasomal degradation and is required for full transcriptional activity of the receptor. Mol Endocrinol 21: 2427–2439.
[26]
Lonard DM, Nawaz Z, Smith CL, O'Malley BW (2000) The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol Cell 5: 939–948.
[27]
Fan M, Nakshatri H, Nephew KP (2004) Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation. Mol Endocrinol 18: 2603–2615.
[28]
Krishnan V, Wang XH, Safe S (1994) Estrogen Receptor-Sp1 Complexes Mediate Estrogen-Induced Cathepsin-D Gene-Expression in Mcf-7 Human Breast-Cancer Cells. Journal of Biological Chemistry 269: 15912–15917.
[29]
Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL (1990) Cathepsin D and prognosis in breast cancer. N Engl J Med 322: 297–302.
[30]
Berchem G, Glondu M, Gleizes M, Brouillet JP, Vignon F, et al. (2002) Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene 21: 5951–5955.
[31]
Kazi AA, Koos RD (2007) Estrogen-induced activation of hypoxia-inducible factor-1 alpha, vascular endothelial growth factor expression, and edema in the uterus are mediated by the phosphatidylinositol 3-kinase/Akt pathway. Endocrinology 148: 2363–2374.
[32]
Fritz WA, Wang J, Eltoum IE, Lamartiniere CA (2002) Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. Mol Cell Endocrinol 186: 89–99.
[33]
Cho SD, Lee SO, Chintharlapalli S, Abdelrahim M, Khan S, et al. (2010) Activation of nerve growth factor-induced B alpha by methylene-substituted diindolylmethanes in bladder cancer cells induces apoptosis and inhibits tumor growth. Mol Pharmacol 77: 396–404.
[34]
Matthews J, Gustafsson JA (2003) Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv 3: 281–292.
[35]
Safe S, Kim K (2008) Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J Mol Endocrinol 41: 263–275.
[36]
Stelzl U, Worm U, Lalowski M, Haenig C, Brembeck FH, et al. (2005) A human protein-protein interaction network: a resource for annotating the proteome. Cell 122: 957–968.
[37]
Onn I, Aono N, Hirano M, Hirano T (2007) Reconstitution and subunit geometry of human condensin complexes. EMBO J 26: 1024–1034.
[38]
Wood JL, Liang Y, Li K, Chen J (2008) Microcephalin/MCPH1 associates with the Condensin II complex to function in homologous recombination repair. J Biol Chem 283: 29586–29592.
[39]
Debnath J, Muthuswamy SK, Brugge JS (2003) Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30: 256–268.
[40]
Latil A, Bieche I, Vidaud D, Lidereau R, Berthon P, et al. (2001) Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 61: 1919–1926.
[41]
Chang C, Norris JD, Gron H, Paige LA, Hamilton PT, et al. (1999) Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta. Mol Cell Biol 19: 8226–8239.
[42]
Fujita N, Jaye DL, Kajita M, Geigerman C, Moreno CS, et al. (2003) MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 113: 207–219.
[43]
Khaleque MA, Bharti A, Gong J, Gray PJ, Sachdev V, et al. (2007) Heat shock factor 1 represses estrogen-dependent transcription through association with MTA1. Oncogene.
[44]
Chen LM, Skinner ML, Kauffman SW, Chao J, Chao L, et al. (2001) Prostasin is a glycosylphosphatidylinositol-anchored active serine protease. J Biol Chem 276: 21434–21442.
[45]
Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359–377.
[46]
Li S, Han B, Liu G, Ouellet J, Labrie F, et al. (2010) Immunocytochemical Localization of Sex Steroid Hormone Receptors in Normal Human Mammary Gland. J Histochem Cytochem 58: 509–515.
[47]
Ellis CM, Dyson MJ, Stephenson TJ, Maltby EL (2005) HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol 58: 710–714.
[48]
Tsunoda N, Kokuryo T, Oda K, Senga T, Yokoyama Y, et al. (2009) Nek2 as a novel molecular target for the treatment of breast carcinoma. Cancer Science 100: 111–116.
[49]
Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863–14868.
